454 related articles for article (PubMed ID: 20724385)
21. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].
Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M
Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312
[TBL] [Abstract][Full Text] [Related]
22. Fidaxomicin: a new option for the treatment of Clostridium difficile infection.
Johnson AP; Wilcox MH
J Antimicrob Chemother; 2012 Dec; 67(12):2788-92. PubMed ID: 22865382
[TBL] [Abstract][Full Text] [Related]
23. Fidaxomicin, a new treatment for Clostridium difficile infections.
Epstein L; Golan Y
Drugs Today (Barc); 2012 Feb; 48(2):101-8. PubMed ID: 22384450
[TBL] [Abstract][Full Text] [Related]
24. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
[TBL] [Abstract][Full Text] [Related]
25. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
27. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection.
Gallagher JC; Reilly JP; Navalkele B; Downham G; Haynes K; Trivedi M
Antimicrob Agents Chemother; 2015 Nov; 59(11):7007-10. PubMed ID: 26324268
[TBL] [Abstract][Full Text] [Related]
28. Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.
Deshpande A; Hurless K; Cadnum JL; Chesnel L; Gao L; Chan L; Kundrapu S; Polinkovsky A; Donskey CJ
Antimicrob Agents Chemother; 2016 Jul; 60(7):3988-93. PubMed ID: 27090175
[TBL] [Abstract][Full Text] [Related]
29. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.
Yamaguchi T; Konishi H; Aoki K; Ishii Y; Chono K; Tateda K
J Infect Chemother; 2020 May; 26(5):483-491. PubMed ID: 32165071
[TBL] [Abstract][Full Text] [Related]
30. Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
Sullivan KM; Spooner LM
Ann Pharmacother; 2010 Feb; 44(2):352-9. PubMed ID: 20071495
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Clostridium difficile infections.
Soriano MM; Johnson S
Infect Dis Clin North Am; 2015 Mar; 29(1):93-108. PubMed ID: 25573676
[TBL] [Abstract][Full Text] [Related]
32. A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
Burton HE; Mitchell SA; Watt M
Pharmacoeconomics; 2017 Nov; 35(11):1123-1140. PubMed ID: 28875314
[TBL] [Abstract][Full Text] [Related]
33. Fidaxomicin: a macrocyclic antibiotic for the treatment of Clostridium difficile infection.
Hardesty JS; Juang P
Pharmacotherapy; 2011 Sep; 31(9):877-86. PubMed ID: 21923589
[TBL] [Abstract][Full Text] [Related]
34. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
35. [Clostridium difficile infecion--diagnostics, prevention and treatment].
Piekarska M; Wandałowicz AD; Miigoć H
Pol Merkur Lekarski; 2014 Apr; 36(214):278-82. PubMed ID: 24868904
[TBL] [Abstract][Full Text] [Related]
36. Safety analysis of fidaxomicin in comparison with oral vancomycin for Clostridium difficile infections.
Weiss K; Allgren RL; Sellers S
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S110-5. PubMed ID: 22752858
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
[TBL] [Abstract][Full Text] [Related]
38. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
[TBL] [Abstract][Full Text] [Related]
39. Fidaxomicin for treatment of clostridium difficile-associated diarrhea and its potential role for prophylaxis.
Hostler CJ; Chen LF
Expert Opin Pharmacother; 2013 Aug; 14(11):1529-36. PubMed ID: 23683070
[TBL] [Abstract][Full Text] [Related]
40. Comparative effectiveness of Clostridium difficile treatments: a systematic review.
Drekonja DM; Butler M; MacDonald R; Bliss D; Filice GA; Rector TS; Wilt TJ
Ann Intern Med; 2011 Dec; 155(12):839-47. PubMed ID: 22184691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
